Driven primarily by continued uptake of Shires market leading ADHD drug, Adderall XR (amphetamine extended release), seven major market ADHD revenues grew strongly at a compound annual growth rate (200408) of 13.5% to reach almost $4.4 billion in 2008. Ongoing uptake of Shires Vyvanse (lisdexamfetamine), was also a key contributor to market growth between 2007 and 2008.
Key reasons to purchase this title
- This report gives a strategic analysis of the likely impact that recent events will have on the future ADHD market.
- Includes sales forecasts for the key ADHD brands and generics as well as pipeline agents in the seven major markets to 2018.
- Quantify the current and future size of the seven major ADHD markets.
